Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nuvectis Pharma (NVCT) Operating Expenses (2021 - 2026)

Nuvectis Pharma has reported Operating Expenses over the past 6 years, most recently at $6.3 million for Q1 2026.

  • Quarterly results put Operating Expenses at $6.3 million for Q1 2026, up 12.43% from a year ago — trailing twelve months through Mar 2026 was $28.3 million (up 34.48% YoY), and the annual figure for FY2025 was $28.0 million, up 38.74%.
  • Operating Expenses reached $6.3 million in Q1 2026 per NVCT's latest filing, down from $7.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $7.8 million in Q3 2025 and bottomed at $2.0 million in Q1 2022.
  • Median Operating Expenses over the past 5 years was $5.9 million (2022), compared with a mean of $5.6 million.
  • Peak annual rise in Operating Expenses hit 8617.39% in 2022, while the deepest fall reached 39.83% in 2022.
  • Over 5 years, Operating Expenses stood at $6.8 million in 2022, then grew by 1.3% to $6.9 million in 2023, then decreased by 6.07% to $6.4 million in 2024, then grew by 18.11% to $7.6 million in 2025, then dropped by 17.82% to $6.3 million in 2026.
  • Business Quant data shows Operating Expenses for NVCT at $6.3 million in Q1 2026, $7.6 million in Q4 2025, and $7.8 million in Q3 2025.